Immunovant, Inc.
For the period ended Dec 10, 2025. Filed Dec 11, 2025.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Dec 10, 2025 · Filed Dec 11, 2025
Use the contents to explore the available documents and sections.
Contents
Clinical Program Updates
IMVT-1402 Potentially Registrational Trial in Difficult-to-Treat Rheumatoid Arthritis (“D2T RA”)
Immunovant, Inc. (“we”) initiated a potentially registrational trial evaluating IMVT-1402 in anti-citrullinated protein autoantibody (“ACPA”) positive D2T RA in December 2024. We continue to expect to report initial results from the period 1 open label portion of this trial in 2026. We now also expect to report top line results from this trial in 2026.
Other Clinical Programs
Other than the D2T RA update above, we continue to expect to meet our previously disclosed anticipated milestones, including for the two potentially registrational trials evaluating IMVT-1402 in adults with Graves’ Disease, for which we expect to reporttop-line results in 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.